Natasha Kolomeyer is an Ophthalmology physician affiliated with Thomas Jefferson University. OpenAlex indexes 64 publications with 349 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
840 Walnut St Ste 1110
Philadelphia, PA 191075109
Telephone
215-928-3197Registry record last updated 21 Jul 2022.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year20251 payment
- Mallinckrodt Hospital Products Inc.Program year20251 payment
- Astellas Pharma US IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
92.1%Prostaglandin Analog32.2%Latanoprost75%Travoprost13%Lumigan10%Zioptan1%Travatan Z1%Part D<11 patientsCarbonic Anhydrase Inhibitor25.3%Dorzolamide-Timolol52%Dorzolamide Hcl28%Simbrinza12%Brinzolamide4%Acetazolamide3%Azopt2%Part D<11 patients+ 6 more classes in this area
Cardiovascular
5.1%Beta blocker5.1%Timolol Maleate100%Part D<11 patientsMusculoskeletal
2%Cyclooxygenase Inhibitor2%Ketorolac Tromethamine100%Part D≥31 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- One-Year Real-World Outcomes of Ab-Externo Gel Stent Placement From the EXPAND Study
Journal of Glaucoma
2025 - Comparison of outcomes of continuous-wave and micropulse trans-scleral cyclophotocoagulation: A retrospective cohort study
European Journal of Ophthalmology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Carol Shields, MD
Thomas Jefferson University
Joseph Bavaria, MD
Thomas Jefferson University
Michele Meltzer, MD
Thomas Jefferson University
Marinos Dalakas, MD
Thomas Jefferson University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”